{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:32:28Z","timestamp":1783035148357,"version":"3.54.6"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1124\/dmd.105.006148","type":"journal-article","created":{"date-parts":[[2005,12,29]],"date-time":"2005-12-29T01:13:12Z","timestamp":1135818792000},"page":"440-448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE"],"prefix":"10.1016","volume":"34","author":[{"given":"Yan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elinore F.","family":"McCance-Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.105.006148_bib1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"Perspective: the conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/00498258109045291","article-title":"Biliary excretion, metabolism and enterohepatic circulation of buprenorphine.","volume":"11","author":"Brewster","year":"1981","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.006148_bib3","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00228-004-0856-7","article-title":"Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes.","volume":"60","author":"Chang","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.105.006148_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0090-9556(25)07765-7","article-title":"The metabolism and excretion of buprenorphine in humans.","volume":"12","author":"Cone","year":"1984","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1476-5381.1977.tb07532.x","article-title":"Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.","volume":"60","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.105.006148_bib6","first-page":"180","article-title":"Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research.","volume":"26","author":"Crespi","year":"1995","journal-title":"Adv Drug Res"},{"key":"10.1124\/dmd.105.006148_bib7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist.","volume":"297","author":"Huang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.006148_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/01.ftd.0000197094.92559.b4","article-title":"The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-electrospray ionizationtandem mass spectrometry.","author":"Huang","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.105.006148_bib9","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0024-3205(97)00160-4","article-title":"Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes.","volume":"60","author":"Iribarne","year":"1997","journal-title":"Life Sci"},{"key":"10.1124\/dmd.105.006148_bib10","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence.","volume":"343","author":"Johnson","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.105.006148_bib11","first-page":"818","article-title":"Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4.","volume":"26","author":"Kobayashi","year":"1998","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib12","first-page":"1410","article-title":"Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9 and 2C19.","volume":"29","author":"Krausz","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1124\/dmd.105.006148_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/00008571-200309000-00005","article-title":"Differential expression and function of CYP2C isoforms in human intestine and liver.","volume":"13","author":"Lapple","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.105.006148_bib15","first-page":"123","article-title":"Ring C-bridged derivatives of thebaine and oripavine.","volume":"8","author":"Lewis","year":"1973","journal-title":"Adv Biochem Psychopharmacol"},{"key":"10.1124\/dmd.105.006148_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/abio.2002.5673","article-title":"A liquid chromatographic-electrospray ionization-tandem mass spectrometric method for determination of buprenorphine, its metabolites, norbuprenorphine and a coformulant, naloxone, that is suitable for in vivo and in vitro metabolism studies.","volume":"306","author":"Moody","year":"2002","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.105.006148_bib17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1006\/bbrc.2001.5054","article-title":"Differential N-demethylation of l-a-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18 and 3A4.","volume":"284","author":"Neff","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.105.006148_bib18","first-page":"319","article-title":"Variables in human liver microsome preparation: impact on the kinetics of L-\u03b1-acetylmethadol (LAAM) N-demethylation and dextromethorphan O-demethylation.","volume":"29","author":"Nelson","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-9556(25)06500-6","article-title":"Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes.","volume":"23","author":"Newton","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-3565(25)24425-1","article-title":"Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling.","volume":"272","author":"Ohtani","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.006148_bib21","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1124\/dmd.105.003681","article-title":"In vitro metabolism study of buprenorphine: evidence for new metabolic pathways.","volume":"33","author":"Picard","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0378-4347(01)00029-9","article-title":"Simultaneous determination of buprenorphine, norbuprenorphine and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry.","volume":"754","author":"Polettini","year":"2001","journal-title":"J Chromatogr B"},{"key":"10.1124\/dmd.105.006148_bib23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/00498258509045363","article-title":"Disposition in the rat of buprenorphine administered parenterally and as a subcutaneous implant.","volume":"15","author":"Pontani","year":"1985","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.006148_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/004982500237541","article-title":"Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450.","volume":"30","author":"Sai","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.006148_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-199602000-00010","article-title":"Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis and addiction severity index.","volume":"16","author":"Strain","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.105.006148_bib26","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0090-9556(24)13680-X","article-title":"Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.","volume":"28","author":"Venkatakrishnan","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib27","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","article-title":"Acute administration of buprenorphine in humans: partial agonist and blockade effects.","volume":"274","author":"Walsh","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.006148_bib28","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses.","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.006148_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1124\/dmd.30.6.631","article-title":"Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.","volume":"30","author":"Wen","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.006148_bib30","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.bcp.2003.08.004","article-title":"Effects of cytochrome b5 on drug oxidation activites of human cytochrome (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7.","volume":"66","author":"Yamaori","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.105.006148_bib31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0090-9556(24)14891-X","article-title":"Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin and imipramine metabolism.","volume":"27","author":"Yang","year":"1999","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562403424X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562403424X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.105.006148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:00:43Z","timestamp":1739901643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562403424X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["S009095562403424X"],"URL":"https:\/\/doi.org\/10.1124\/dmd.105.006148","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NOVEL METABOLITES OF BUPRENORPHINE DETECTED IN HUMAN LIVER MICROSOMES AND HUMAN URINE","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.105.006148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2006 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}